RB101-mediated protection of endogenous opioids: Potential therapeutic utility?

CNS Drug Reviews

Volumn 13, Issue 2, 2007, Pages 192-205

  Jutkiewicz, Emily M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antinociception; Anxiety; Depression; Enkephalins; Opioids; RB101

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ACETYLSALICYLIC ACID; CHOLECYSTOKININ; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; LEUCINE ENKEPHALIN; MEMBRANE METALLOENDOPEPTIDASE; METENKEPHALIN; MICROSOMAL AMINOPEPTIDASE; MORPHINE; MU OPIATE RECEPTOR; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; OPIATE; PARACETAMOL;

ANALGESIA; ANTINOCICEPTION; ANXIETY DISORDER; DEPRESSION; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TOLERANCE; EMOTION; ENZYME INHIBITION; FORCED SWIMMING TEST; HOT PLATE TEST; LEARNED HELPLESSNESS; LIPOPHILICITY; MOLECULAR INTERACTION; MOOD; NONHUMAN; PAIN; PLACE PREFERENCE; RESPIRATION DEPRESSION; REVIEW; SUSTAINED DRUG RELEASE; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

AMINOPEPTIDASES; ANIMALS; CHOLECYSTOKININ; DISULFIDES; ENKEPHALIN, LEUCINE; ENKEPHALIN, METHIONINE; ENZYME INHIBITORS; MICE; PHENYLALANINE; PRODRUGS; RATS;

EID: 34447296676     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2007.00011.x     Document Type: Review

References (65)

1. Abbadie C, Honoré P, Fournié-Zaluski MC, Roques BP, Besson J-M (1994) Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rats lumbar spinal cord neurons by noxious heat stimulation. Eur J Pharmacol 258 : 215 227.
2. Albiston AL, Ye S, Chai SY (2004) Membrane bound members of the M1 family: More than aminopeptidases. Prot Peptide Lett 11 : 491 500.
3. Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D1 receptor stimulation. Eur J Pharmacol 216 : 157 166.
4. Bals-Kubik R, Shippenberg TS, Herz A (1990) Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat. Eur J Pharmacol 175 : 63 69.
5. Boudinot E, Morin-Surun MP, Foutz AS, Fournié-Zaluski MC, Roques BP, Denavit-Saubié M (2001) Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration. Pain 90 : 7 13.
6. Bourgoin S, Le Bars D, Artaud F, Clot AM, Bouboutou R, Fournié-Zaluski MC, Roques BP, Hamon M, Cesselin F (1986) Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like material from rat spinal cord. J Pharmacol Exp Ther 238 : 360 366.
7. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002) Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacol 26 (6 744 755.
8. Carenzi A, Frigeni V, Reggiani A, Della Bella D (1983) Effect of inhibition of neuropeptidases on the pain threshold of mice and rats. Neuropharmacology 22 : 1315 1319.
9. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang K-J, De Costa BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267 (2 888 895.
10. Cordonnier L, Sanchez M, Roques BP, Noble F (2005) Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neurosci 135 : 1 10.
11. Coudoré-Civiale M-A, Méen M, Fournié-Zaluski MC, Boucher M, Roques BP, Eschalier A (2001) Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats. Br J Pharmacol 133 : 179 185.
12. Covington III. HE, Miczek KA (2003) Vocalizations during withdrawal from opiates and cocaine: Possible expression of affective distress. Eur J Pharmacol 467 : 1 13.
13. Danielsson I, Gasior M, Stevenson GW, Folk JE, Rice KC, Negus SS (2006) Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav 85 : 428 434.
14. Daugé V, Mauborgne A, Cesselin F, Fournié-Zaluski MC, Roques BP (1996) The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of met-enkephalin-like material in the nucleus accumbens of freely moving rats. J Neurochem 67 : 1301 1308.
15. Devine DP, Wise RA (1994) Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci 14 : 1978 1984.
16. Dickenson AH, Sullivan AF, Fournié-Zaluski MC, Roques BP (1987) Prevention of degradation of endogenous enkephalins produces inhibition of nociceptive neurons in rat spinal cord. Brain Res 408 : 185 191.
17. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, et al 2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nature 25 : 195 200.
18. Fournié-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, Roques BP (1992a) Potent and systemically active aminopeptidase N inhibitors designed from active site investigation. J Med Chem 35 : 1259 1266.
19. Fournié-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, Maldonado R, Roques BP (1992b) "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem 35 : 2473 2481.
20. Gacel GA, Fellion E, Baamonde A, Dauge V, Roques BP (1990) Synthesis, biochemical and pharmacological properties of BUBUC, a highly selective and systemically active agonist for in vivo studies of δ-opioid receptors. Peptides 11 : 983 988.
21. Hernando F, Fuentes JA, Fournié-Zaluski MC, Roques BP, Ruiz-Gayo M (1996) Antidepressant-like effects of CCKB receptor antagonists: involvement of the opioid system. Eur J Pharmacol 318 : 221 229.
22. Honoré P, Buritova J, Fournié-Zaluski MC, Roques BP, Besson JM (1997) Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats. J Pharmacol Exp Ther 281 : 208 217.
23. Jardinaud F, Crété D, Canestrelli C, Ledent C, Roques BP, Noble F (2005) CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res 1063 : 77 83.
24. Jayaram A, Singh P, Noreuil T, Fournié-Zaluski MC, Carp HM (1997) RB 101, a purported pro drug inhibitor of enkephalin metabolism, is antinociceptive in pregnant mice. Anesth Analg 84 : 355 358.
25. Jutkiewicz EM, Eller EB, Folk JE, Rice KC, Traynor JR, Woods JH (2004) Delta-opioid agonists: Differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther 309 : 173 181.
26. Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH (2006) Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur J Pharmacol 531 : 151 159.
27. Knisely JS, Beardsley PM, Aceto MD, Balster RL, Harris LS (1989) Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor. Drug Alcohol Depend 23 : 143 151.
28. Koeltzow TE, White FJ (2003) Behavioral depression during cocaine withdrawal is associated with decreased spontaneous activity of ventral tegmental area dopamine neurons. Behav Neurosci 117 : 860 865.
29. Lee PH, McNutt RW, Chang KJ (1993) A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J Pharmacol Exp Ther 267 : 883 887.
30. Le Guen S, Honoré P, Catheline G, Fournié-Zaluski MC, Roques BP, Besson JM (1999) The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced c-Fos expression are completely blocked by β-funaltrexamine, a selective μ-opioid receptor antagonist. Brain Res 834 : 200 206.
31. Le Guen S, Noble F, Fournié-Zaluski MC, Roques BP, Besson J-M, Buritova J (2002) RB101(S), a dual inhibitor or enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: A c-Fos study at the spinal level. Eur J Pharmacol 441 : 141 150.
32. Le Guen S, Catheline G, Fournié-Zaluski MC, Roques BP, Besson JM, Buritova J (2003a) Further evidence for the interaction of μ- and δ-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S). A spinal c-Fos protein study in the rat under carrageenin inflammation. Brain Res 967 : 106 112.
33. Le Guen S, Mas Nieto M, Canestrelli C, Chen H, Fournié-Zaluski MC, Cupo A, Maldonado R, Roques BP, Noble F (2003b) Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone. Pain 104 : 139 148.
34. Le Guen S, Noble F, Fournié-Zaluski MC, Roques BP, Besson JM, Buritova J (2002) RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: A c-Fos study at the spinal level. Eur J Pharmacol 441 : 141 150.
35. Maldonado R, Daug V, Callebert J, Villette JM, Fournié-Zaluski MC, Fger J, Roques BP (1989) Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine-withdrawal syndrome. Eur J Pharmacol 165 : 199 207.
36. Maldonado R, Valverde O, Turcaud S, Fournié-Zaluski MC, Roques BP (1994) Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain 58 : 77 83.
37. Mas Nieto M, Wilson J, Walker J, Benavides J, Fournié-Zaluski MC, Roques BP, Noble F (2001) Facilitation of enkephalin catabolism inhibitor-induced antinociception by drugs classically used in pain management. Neuropharmacol 41 : 496 506.
38. Mas Nieto M, Guen SLE, Kieffer BL, Roques BP, Noble F (2005) Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neurosci 135 : 305 313.
39. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud M, Fournié-Zaluski MC, Roques BP (1992a) Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261 : 181 190.
40. Noble F, Turcaud S, Fournié-Zaluski MC, Roques BP (1992b) Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur J Pharmacol 223 : 83 89.
41. Noble F, Coric P, Fournié-Zaluski MC, Roques BP (1992c) Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101. Eur J Pharmacol 223 : 91 96.
42. Noble F, Fournié-Zaluski MC, Roques BP (1993) Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice. Eur J Pharmacol 230 : 139 149.
43. Noble F, Coric P, Turcaud S, Fournié-Zaluski MC, Roques BP (1994) Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB101. Eur J Pharmacol 253 : 283 287.
44. Noble F, Blommaert A, Fournié-Zaluski MC, Roques BP (1995) A selective CCKB receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test. Eur J Pharmacol 273 : 145 151.
45. Noble F, Roques BP (1995) Assessment of endogenous enkephalins efficacy in the hot plate test in mice: Comparative study with morphine. Neurosci Lett 185 : 75 78.
46. Noble F, Fournié-Zaluski MC, Roques BP (1996) Opposite role of δ1- and δ2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: Further evidence for δ-opioid receptor heterogeneity. Neurosci 75 : 917 926.
47. Noble F, Smadja C, Valverde O, Maldonado R, Coric P, Turcaud S, Fournié-Zaluski MC, Roques BP (1997) Pain-suppresive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120. Pain 73 : 383 391.
48. Ortega-Alvaro A, Chover-Gonzalez AJ, Lai-Kuen R, Mico JA, Gibert-Rahola J, Fournié-Zaluski MC, Roques BP, Maldonado R (1998) Antinociception produced by the peptidase inhibitor, RB101, in rats with adrenal medullary transplant into the spinal cord. Eur J Pharmacol 356 : 139 148.
49. Ouellet DMC, Pollack GM (1997) Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats. J Pharmacol Exp Ther 281 : 713 720.
50. Roques BP, Fournié-Zaluski MC (1989) Enkephalin degrading enzyme inhibitors: A physiological way to new analgesics and psychoactive agents. NIDA Res Monogr 70 : 128 154.
51. Ruiz-Gayo M, Baamonde A, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: Blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding. Brain Res 571 : 306 312.
52. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective δ-opioid agonist, in behavioral models in rodent. J Pharmacol Sci 95 : 374 380.
53. Shippenberg TS, Bals-Kubik R, Herz A (1987) Motivational properties of opioids: Evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res 436 : 234 239.
54. Smadja C, Maldonado R, Turcaud S, Fournié-Zaluski MC, Roques BP (1995) Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology 120 : 400 408.
55. Smadja C, Ruiz F, Coric P, Fournié-Zaluski MC, Roques BP, Maldonado R (1997) CCK-B receptor in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology 132 : 227 236.
56. Sumitomo M, Shen R, Nanus DM (2005) Involvement of neutral endopeptidase in neoplastic progression. Biochimica et Biophysica Acta 1751 : 52 59.
57. Suzuki T, Tsuji M, Mori T, Misawa M, Nagase H (1996) The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of δ1 and δ2 opioid receptor agonists in mice. Psychopharmacology 124 : 211 218.
58. Tejedor-Real P, Micó JA, Smadja C, Maldonado R, Roques BP, Gibert-Rahola J (1998) Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354 : 1 7.
59. Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270 : 77 88.
60. Valverde O, Blommaert AGS, Fournié-Zaluski MC, Roques BP, Maldonado R (1995) Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Eur J Pharmacol 286 : 79 93.
61. Valverde O, Fournié-Zaluski MC, Roques BP, Maldonado R (1996) Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. Eur J Pharmacol 312 : 15 25.
62. Vergura R, Valenti E, Hebbes CP, Gavioli EC, Spagnolo B, McDonald J, Lambert DC, Balboni G, Salvadori S, Regoli D, et al 2006) Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides.
63. Waksman G, Hamel E, Fournié-Zaluski MC, Roques BP (1986) Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of μ and δ opioid receptors in rats brain. Proc Natl Acad Sci USA 83 : 1523 1527.
64. Wiesenfeld-Hallin Z, Lucas GA, Alster P, Xu X-J, Hökfelt T (1999) Cholecystokinin/opioid interactions. Brain Res 848 : 78 89.
65. Xu X-J, Elfvin A, Hao JK, Fournié-Zaluski MC, Roques BP, Wiesenfeld-Hallin Z (1997) CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides 31 : 287 291.